10x Genomics, Inc. cash flow to debt ratio of 86.25% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

10x Genomics, Inc.'s free cash flow has increased -2.37K% from $-5.73M last year to $130.12M, signaling increasing performance

10x Genomics, Inc.'s debt to equity ratio is 0.10, which means that the company's assets are healthy financed, signaling financial stability.

10x Genomics, Inc.'s debt has decreased relative to shareholder equity from 0.12 last year to 0.10 today, signaling strengthened financials

10x Genomics, Inc. has a net cash position, so leverage is healthy.

10x Genomics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

10x Genomics, Inc.'s profit margin has increased (-59.27%) in the last year from -29.90% to -12.18%, signaling increasing performance

10x Genomics, Inc.'s short-term assets of $684.45M exceed its short-term liabilities of $153.45M

10x Genomics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

10x Genomics, Inc.'s return on equity of -9.33%, is lower than 15.00%, indicating bad performance

10x Genomics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

10x Genomics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

10x Genomics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

10x Genomics, Inc. has a free cash flow yield of 1.75%, which is below the 2.00% threshold, indicating limited cash return relative to market value

10x Genomics, Inc.'s yearly earnings has increased -76.16% since last year from $-182.63M to $-43.54M, signaling increasing performance

10x Genomics, Inc.'s yearly revenue has increased 5.25% since last year from $610.78M to $642.82M, signaling increasing performance

ROIC -9.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

10x Genomics, Inc.'s 3-year revenue CAGR of 7.57% is positive, indicating growing revenue over the past 3 years

10x Genomics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

10x Genomics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

10x Genomics, Inc. has insufficient data to evaluate this check.

10x Genomics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

10x Genomics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

10x Genomics, Inc. has an EV/EBITDA ratio of 1.81Kx, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

10x Genomics, Inc. is overvalued relative to its fair value price of -31.77 based on Earnings Fair Value model

10x Genomics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

10x Genomics, Inc. has a price-to-book ratio of 9.22x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

10x Genomics, Inc. has a price-to-sales ratio of 12.34x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue